Clinical Research: Phase 1 - Phase 4

Clinical Research: Phase 1 - Phase 4

Welcome to Premier Perspectives!

Thanks for visiting the newest addition to our website, our Premier Perspectives blog! Our goal?  To give Premier People the chance to share and discuss their industry insights and ideas with customers, colleagues, patients, employees, and basically, anyone who’s interested in clinical research. We believe in improving productivity in clinical development, and sharing our ideas and best...

Clinical Research: Phase 1 - Phase 4

Premier Insight 265: Exceeding Expectations: Durable Remission in Diffuse Large B-Cell Lymphoma

When a developer of a CD19-directed cytolytic antibody for B-cell Lymphoma engaged Premier Research to assist with screening and enrollment in a global Phase 2 study, the Premier project team devised an operational strategy with a goal to exceed expectations. Despite several challenges, the enrollment was completed three months ahead of schedule thanks to consistent...

Clinical Research: Phase 1 - Phase 4

Premier Insight 258: Glioblastoma Drug Study Yields ‘Unexpectedly Huge’ Advance

A three-nation study of a treatment for recurring glioblastoma showed the therapy more than five times as effective as the typical protocol, an unexpectedly large advance in fighting these aggressive brain tumors. But it was a long road, and the drug’s efficacy was a big factor in extending the trial to five years — nearly...

Clinical Research: Phase 1 - Phase 4

Premier Insight 256: A Talent for Resolving Unusually Complex Issues

A customer came to us with a seven-year project to develop a novel human antibody from scratch, to treat multiple myeloma. There were no benchmarks, no relevant data on similar compounds because there were no similar compounds. The first challenge: engage key opinion leaders This project was never going to be easy or “by the...

Clinical Research: Phase 1 - Phase 4

Rare Oncology Research in the 21st Century

Speakers: Sachin KulkarniExecutive Director, Strategic Development, Oncology & General MedicinePremier Research Juliet M. MoritzExecutive Director, Strategic Development, Rare DiseasesPremier Research Study of rare cancers tends to look more like rare disease research than standard oncology research. This webinar will highlight some of the challenges in designing and conducting trials for rare cancers and explore positions...

Clinical Research: Phase 1 - Phase 4

Rare Disease Trials: The Beginning, the Middle and the End

Speaker: Angi Robinson, Executive Director, Pediatrics and Rare Diseases, Premier Research This session includes a regulatory overview of rare diseases and orphan drug status as well as practical considerations for varying stages of the development process. Viewers will learn more about conducting successful Natural History studies and the presenters will review how to avoid common...

Clinical Research: Phase 1 - Phase 4

Measuring How Well Subjects Know and Do in CNS Trials

Central nervous system (CNS) disorders represent a major medical challenge and a significant opportunity for therapeutic innovation. Sponsors who have a clear understanding of the regulatory landscape and neuropsychological testing modalities available are poised to address critical unmet needs for the millions of people living with CNS conditions. Central nervous system (CNS) conditions, including psychiatric,...